look forward grow aducanumab alzheim diseas
recommend hold rate upgrad tp
provid upsid potenti
estim adjust ep
respect estim
forward price-to-earnings multipl
demonstr strong execut across core
busi area resili ms continu strong
world-wide growth spinraza expand biosimilar
addit part expand pipelin excit
prospect aducanumab alzheim diseas
look forward complet regulatori file
soon possibl fact stock surg sinc octob
announc seek fda approv
alzheim therapi initi fail pivot trial
benefit warrant fda consider
howev compani expect revenu rang
therefor expect declin
revenu compani still get approv
aducanumab expect mid- late-stag data readout
end
total revenu increas
estim adjust ep increas
estim
mn except ep
compani name inc tickerbiibstock ratingholddowngradeindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| februari
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
multipl sclerosi ms revenu includ
royalti sale ocrevu increas
spinraza revenu increas y/i
biosimilar revenu increas
channel inventori level increas
tecfidera vumer avonex
plegridi tysabri combin spinraza
revenu compris sale
sale outsid number
commerci patient receiv spinraza grew
 outsid versu
recent patent challeng billion-dollar
ms drug tecfidera unless appeal
on-going patent challeng result differ rule
mean stave tecfidera competit
patent expir share surg much
announc final close
higher previou close price
pipelin grown matur
ad new clinic program look forward
multipl near-term opportun valu creation
includ alzheim diseas al stroke lupu
ophthalmolog biosimilar aim build
downgrad rate hold
declin revenu growth
cautiou revenu growth compani
still get approv drug growth driver
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date jan inform biogen inc| februari
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement growth growth good gener administr expens develop expens amort income/expens oper oper expens net capit invest income/expens incom equiti interest incom extraordinari item discontinu incom avail common incom growth incom growth ep growth weight averag share outstand annual actual annual actual quarterli inc| februari
balanc sheet item short term invest total st account receiv total receiv inventori prepaid expens -- -- -other current asset total current asset gross properti plant accumul depreci net properti plant equip long-term invest tangibl defer tax asset long-term asset total asset equiti liabil account payabl accru expens current portion lt debt incom tax payabl current liabil total current liabil long-term capit leas def tax liabil non-curr liabil total liabil common stock retain earn treasuri stock comprehens incom total common minor interest total equiti total liabil equiti actual quarterli actual annual inc| februari
net cash flow provid oper activ increas compar
due chang fair valu conting payment associ
compani acquisit busi payment relat collabor
net cash flow provid invest activ declin compar
cash flow due decreas conting payment made former sharehold
fumapharm ag holder right proce receiv upon divestitur compani
hillerd denmark manufactur oper proce receiv compani sale strateg
invest payment made ioni reflect fair valu ioni common
stock purchas upon close ioni agreement prior year compar period
net cash use financ activ decreas compar
due due increas cash use share repurchas
incom depreci amort goodwil intang depreci amort total loss sale asset loss sale invest -- stock-bas compens oper activ chang account receiv chang inventori chang net oper asset oper invest activ capit expenditur acquisit -- invest market equiti secur invest activit invest financ activ long-term debt issu -- total debt issu -- long-term debt repaid total debt repaid issuanc common stock -- repurchas common stock common prefer stock dividend paid -- financ chang equival foreign exchang rate adjust net chang actual annual actual quarterli inc| februari
deliv solid perform global quarter led new
program pipelin
total revenu increas compar
total product revenu increas
compar total revenu
therapeut program increas compar
revenu decreas compar
sale exclud amort impair
acquir intang asset decreas
compar
gross margin perform compar
improv gross margin due slightli lower royalti
well lower cost relat revenu
 expens increas compar
 expens includ relat transact
samsung bioepi relat option exercis ioni relat
relat collabor agreement
therapeut catalyst bioscienc
sg expens increas compar
increas due increas commerci
medic invest well time spend
amort impair acquir intang asset decreas
compar gain
fair valu remeasur conting consider
compar loss
compar
 expens increas
compar
incom oper
increas
compar
collabor profit share show increas
compar incom oper increas
compar
net expens compar
incom tax expens decreas compar
effect tax rate compar
benefit unfavor prior-year effect us
tax reform
net equiti loss investe net incom increas
compar non-gaap
net incom increas compar
gaap ep increas compar
non-gaap ep increas compar
compar
total revenu increas compar
total product revenu increas
compar total revenu therapeut
program increas compar
total revenu increas compar
increas primarili due higher revenu manufactur
suppli agreement bioverativ partial off-set lower revenu
contract manufactur agreement
revenu collabor relationship increas
compar primarili due
servic provid samsung bioepi
royalti corpor revenu increas
compar primarili due
revenu recogn manufactur suppli
agreement bioverativ enter connect spin-off
hemophilia busi compar recogn
increas corpor revenu partial off-set reduct
royalti revenu due expir certain patent reduct
revenu contract manufactur agreement
reserv discount allow gross product revenu
compar
sale exclud amort impair acquir intang
asset increas compar
product cost sale increas
compar increas due sale
bioverativ hemophilia-rel inventori hand decemb
cost basi total pursuant term
manufactur suppli agreement bioverativ enter
connect spin-off hemophilia busi
increas product cost sale also attribut increas
sale product within biosimilar busi increas inventori
amount written result excess obsolesc unmarket
reason partial off-set lower cost sale contract
royalti cost sale decreas compar
decreas due decreas royalti payabl
sale tysabri result expir certain third parti royalti
partial off-set increas royalti payabl higher sale spinraza
product cost sale
increas
compar
royalti cost sale
decreas
compar
 expens decreas compar
mileston up-front
expens increas
compar
research discoveri
mileston up-front expens
decreas
compar
decreas due decreas mileston up-front expens
decreas research develop cost decreas
partial off-set increas cost incur connect earli stage
program market product
mileston up-front expens increas compar
increas due
charg research develop expens upon
complet transact samsung bioepi secur exclus
right commerci two potenti ophthalmolog biosimilar product
charg research develop expens upon exercis
option obtain world-wide exclus royalti bear licens ioni
develop commerci
charg research develop expens consist
charg upon enter collabor research
develop servic agreement skyhawk charg
upon enter amend agreement add addit
late stage program decreas compar
decreas primarili due decreas spend
relat discontinu global phase trial engag
emerg aducanumab net eisai reimburs
compar
earli stage program increas compar
increas earli stage program primarili due
cost associ gosuranemab psp ad pursuant licens
agreement bm cinpanemab parkinson diseas xlrp
cia al ms
actriia/b ligand trap sma decis septemb discontinu
phase studi potenti treatment ipf
compani incur one-tim close charg
sg expens increas compar
increas due increas commerci medic
invest well time spend sell gener
amort impair acquir intang asset decreas
compar decreas
primarili due impact impair charg
relat certain ipr asset associ phase studi
potenti treatment ipf discontinu
expens increas
compar
net profit-shar expens increas compar
increas profit-shar expens
compar period primarili due increas collabor profit
result increas biosimilar sale
gain fair valu remeasur conting consider increas
compar increas
primarili due discontinu phase studi
potenti treatment ipf partial off-set chang probabl
expect time achiev certain development mileston
decreas interest rate use revalu conting consider liabil
passag time
incom oper increas
compar net incom
compar chang net incom primarili
reflect net gain total recogn invest relat
hold equiti debt secur compar net gain total
net gain recogn primarili reflect increas
fair valu invest ioni common stock partial off-set
net loss recogn sale portion invest ioni common
stock reflect decreas fair valu
share sold march
incom tax expens decreas compar
effect tax rate decreas
compar decreas due combin
intern reorgan certain intellectu properti right
impact swiss tax reform
decreas partial off-set tax expens relat
divestitur subsidiari own hillerd denmark manufactur
oper also higher effect tax rate result
unfavor effect tax act sale inventori tax effect
includ within prepaid tax januari higher
effect tax rate statutori tax rate
net equiti loss investe loss reflect
share loss total amort basi differ total
net incom increas compar
gaap ep increas compar
non-gaap ep increas compar
incom oper
increas
compar
net incom increas
compar
total product revenu increas compar
increas compar
increas primarili due increas
revenu spinraza increas revenu biosimilar
busi product revenu reflect unfavor impact
total product revenu decreas
compar drop
compar
total product revenu rest world increas
compar revenu increas
compar
increas
compar
increas
compar
tecfidera revenu increas compar
total revenu increas
compar
total us revenu increas compar
total us revenu increas
compar increas due
slight net price increas off-set small decreas unit sale volum
total revenu rest world increas
compar increas
compar
increas rest world revenu primarili due
increas unit sale volum primarili relat european
japanes market favor impact foreign currenc
exchang partial off-set price reduct certain
anticip increas tecfidera demand rest world
compar notwithstand increas competit
addit treatment ms compani also expect volum
rest world market off-set volum declin
increas
compar
total revenu rest
world increas
compar
decreas
compar
interferon revenu decreas
compar decreas
compar
total us revenu decreas
compar decreas
compar
decreas revenu due decreas interferon unit
sale volum primarili attribut patient
transit ms therapi net price decreas
total revenu rest world decreas
compar decreas
compar
decreas rest world revenu primarili due
price reduct certain european countri
increas
compar
compani expect interferon revenu declin
rest world market compar result
increas competit ms product well
treatment ms includ biosimilar price reduct certain
tysabri revenu increas compar
increas compar
increas
compar
total revenu rest
world decreas
compar
total us revenu increas compar
increas compar
decreas revenu primarili due price increas
partial off-set decreas unit sale volum
total revenu rest world decreas
compar decreas
compar increas
primarili due increas unit sale volum
compani anticip tysabri demand stabl global basi
compar expect volum declin
due increas competit addit treatment ms
includ ocrevu off-set volum growth rest world market net
price reduct certain rest world countri
spinraza revenu increas
compar increas
compar
total us revenu increas compar
increas
compar increas primarili due
increas unit sale volum
total revenu rest world increas
compar total
revenu rest world increas
compar
increas due increas unit sale volum
partial off-set unfavor impact foreign currenc
compani expect rate spinraza revenu grow
moder compar primarili due lower rate
new patient start combin impact load dose dynam
patient transit dose everi four month
increas
compar
increas
compar
new gene therapi
product
approv
may
treatment sma
face competit new gene therapi product
approv may treatment sma addit
awar product develop success
develop approv may compet spinraza sma
market includ potenti oral product futur sale spinraza may
advers affect commerci compet product
benepali flixabi imraldi
increas
compar
biosimilar revenu increas
compar increas
compar
benepali flixabi imraldi
increas primarili due launch imraldi
partial off-set unfavor impact foreign currenc
benepali revenu increas slightli compar
slight increas
compar
flixabi revenu increas compar
increas compar
imraldi revenu
revenu program
compar
share pre-tax
profit
rituxan gazyva
compar
revenu program
revenu therapeut program increas
compar increas due
increas royalti revenu sale ocrevu
share pre-tax profit rituxan gazyva
compar total product
revenu increas
compar
increas due increas net sale rituxan
reflect increas unit sale volum sell
price increas partial off-set higher rate discount
allow increas product revenu also reflect increas
gazyva unit sale volum
decreas collabor cost expens primarili due
lower cost sale lower sell market cost rituxan
lower brand pharmaceut drug fee expens rituxan
increas revenu therapeut program
primarili due sale growth ocrevu royalti revenu
recogn sale ocrevu compar
receiv gross royalti net sale ocrevu outsid
 royalti period last year first commerci
sale ocrevu country-by-countri basi ocrevu
approv treatment rm ppm certain
countri
revenu
increas
compar
share pre-tax
profit
rituxan gazyva
compar
announc agreement
acquir pf-
inhibitor casein kinas
potenti
treatment patient
behavior
neurolog diseas
januari announc agreement acquir pf-
novel cns-penetr small molecul inhibitor casein kinas
potenti treatment patient behavior
neurolog symptom across variou psychiatr neurolog diseas
particular plan develop phase asset treatment
sundown alzheim diseas irregular sleep wake rhythm disord
parkinson diseas purchas includ up-front payment
potenti addit develop
commerci mileston payment well tier royalti high
singl digit sub-teen
transact subject customari close condit includ
expir applic wait period hart-scott-rodino
anti-trust improv act expect close
first quarter
ad seven clinic program pipelin includ
timrepigen emparvovec choroideremia chm rpgr
gene therapi x-link retin pigmentosa btk inhibitor ms
parkinson diseas inhibitor
amyotroph later sclerosi glibenclamid iv brain contus
biosimilar referenc lucenti
decemb enter collabor agreement
collabor leverag
gene circuitri platform aim identifi dial
express disease-associ gene within microgli cell
primari immun cell central nervou system implic
mani seriou neurolog neurodegen diseas term
agreement paid up-front payment
aducanumab
phase emerg
engag studi
clinic trial
ctad annual congress
decemb enter global licens collabor
agreement catalyst bioscienc develop
commerci pegyl cb preclin proteas
potenti treatment geograph atrophi associ dri age-rel
macular degener term agreement paid
catalyst bioscienc up-front payment
decemb complet transact samsung bioepi
secur exclus right commerci two new potenti
ophthalmolog biosimilar referenc lucenti referenc
eylea major market world-wide includ canada europ japan
australia addit acquir exclus commerci right
anti-tnf portfolio includ benepali flixabi imraldi china
also acquir option extend exist commerci agreement
samsung bioepi anti-tnf portfolio europ
decemb announc top-line result phase
passport studi gosuranemab progress supranuclear
palsi psp primari endpoint measur psp rate scale
week statist signific addit studi
demonstr efficaci key clinic secondari endpoint
safeti result passport studi gener consist previou
studi gosuranemab base result discontinu
develop gosuranemab psp primari tauopathi
decemb present top-line data aducanumab
phase emerg engag studi clinic trial alzheim
diseas ctad annual congress san diego california
decemb announc posit top-lin result
phase lilac studi evalu efficaci safeti fulli
express plasmacytoid dendrit cell patient lupu
lilac two-part studi evalu versu placebo
individu activ cutan lupu erythematosu cle includ
chronic subacut subtyp without system manifest
individu system lupu erythematosu sle activ joint
cle sle part studi met primari endpoint safeti
toler profil support continu develop
plan advanc phase
novemb present detail result phase
studi vumer diroximel fumar annual
meet european charcot foundat itali vumer novel
oral fumar distinct chemic structur result
demonstr improv patient-assess gastrointestin gi toler
compar tecfidera dimethyl fumar
novemb complet enrol global phase
clinic studi evalu investig gene therapi
potenti treatment chm chm rare degen x-link
inherit retin disord lead blind current
octob food drug administr approv
vumer treatment relaps form ms includ clinic
isol syndrom relapsing-remit diseas activ secondari
octob announc plan submit regulatori
file aducanumab alzheim diseas base new analysi
larger dataset phase emerg engag studi
phase evolve-
studi vumer
diroximel fumar
annual meet
european charcot
foundat itali
expect revenu rang
expect ep rang non-
ep rang
tax rate expect rang
sg expens expect total revenu
deliv solid perform global compani quarter led
new program pipelin total revenu increas
compar increas
compar
gaap ep increas compar
non-gaap ep increas compar
ep increas compar
non-gaap ep increas
compar
total product revenu increas compar
increas
compar
enter agreement acquir novel asset applic
alzheim parkinson diseas compani report posit phase
data lupu
rang
non-gaap
ep rang
perform global
compani quarter led
new program
compani continu expand market-lead ms portfolio fda
approv vumer show progress stroke enter phase
studi progress acut ischem stroke
demonstr strong execut across core busi area
resili ms continu strong world-wide growth spinraza
expand biosimilar busi
addit part expand pipelin compani excit
prospect aducanumab alzheim diseas look forward
complet regulatori file soon possibl
statist show aducanumab real shot gener well
cumul sale entir life cycl analyst suggest
aducanumab might go becom best-sel drug time
henc biogen stock quadrupl valu next year
made buy-back decemb
compani continu
expand market-lead
ms portfolio fda
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
gross margin compar
net margin improv compar
ep growth compar
revenu growth compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag marginsprofitabilityrevenu growth oper incom growthep growth inc| februari
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale biogen inc| februari
invest flow
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset biogen inc| februari
roe averag oper median roe
howev roe declin due declin net margin due increas tax
biogen net margin biogen asset
turnov constant sinc last
biogen financi leverag increas show
compani leverag peak debt capit structur
financ asset
dupont analysi biogen above-industri roe encourag high roe
driven net margin leverag roe healthcar sector
return invest capit
capit effici ratio use measur firm abil creat valu
stakehold debt equiti firm expect continu gener posit excess return
new invest futur see valu increas growth increas
biogen increas due increas profit decreas
due declin net profit howev increas
biogen averag oper median biogen
healthcar sector
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item biogen inc| februari
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free inc| februari
current price-to-earnings multipl averag price-to-earnings price-to-earnings trail
till januari expect forward price-to-earnings multipl
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock manag group inc street invest manag compani capit manag capit manag world mutual fund holdersholdersharesd report outvaluevanguard/primecap total stock market specialized-health mason clearbridg aggress growth horizon fund-capit opportun etf institut fund-institut etf tr-invesco qqq tr seri inc| februari
developmentsbiogen acquir novel clinic stage asset applic alzheim diseas parkinson diseas inc januari inc announc agreement acquir pfizer inc novel cns-penetr small molecul inhibitor casein kinas potenti treatment patient behavior neurolog symptom across variou psychiatr neurolog diseas particular plan develop phase asset treatment sundown alzheim diseas ad irregular sleep wake rhythm disord iswrd parkinson diseas pd purchas includ up-front payment million million potenti addit develop commerci mileston payment well tier royalti high singl digit sub-teen biogen report top-lin result phase studi supranuclear palsydecemb inc announc top-line result phase passport studi gosuranemab progress supranuclear palsi psp primari endpoint measur psp rate scale pspr week statist signific addit studi demonstr efficaci key clinic secondari endpoint base result discontinu develop gosuranemab psp primari tauopathi biogen present data demonstr improv gastrointestin toler vumer diroximel fumar compar tecfidera dimethyl fumar novemb inc announc detail result phase studi demonstr improv patient-assess gastrointestin gi toler vumer diroximel fumar new fda-approv treatment relaps form multipl sclerosi ms compar tecfidera dimethyl fumar result present meet european charcot foundat itali nov present evercor isi annual healthconx conferencenovemb inc announc present evercor isi annual healthconx confer webcast live tuesday decemb et anirvan ghosh ph senior vice presid head research earli develop access live webcast pleas visit investor section atwww investor biogen com archiv version webcast avail follow present inc| februari
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
consensu view analyst trend stock
low compar
average
forward price-to-earnings
average
biib avgfive-year growth forecast usdgrowth high day day day estim comparisonbiibindustri avg avgprice/earn yield inc| februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr surprisescurr growth rate biogen inc| februari
incom statement
guidanc
non-gapp
return invest
per share item
product perform develop
valuat consensu perform
stock price trade current trade
averag volum share trade
stock price volatil throughout year
stock price gave annual return rang stock
stock price show huge fluctuat past
stock trade declin may
demonstr strong growth result growth revenu due continu
momentum spinraza ocrevu biosimilar revenu recommend hold rate
tp cautiou growth compani
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
